Genentech files data with FDA to get full approval of Avastin in breast cancer
17 November 2009
Malini Guha
Please Login to read the full article.
17 November 2009
Malini Guha
Genentech has submitted data to the US FDA from two Phase III trials, AVADO and RIBBON 1, testing its blockbuster drug Avastin (bevacizumab) as a first-line therapy for metastatic, HER2-negative breast cancer, as part of its effort to convert the drug's accelerated approval for this indication to...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Genentech secures FDA hearing for Avastin in breast cancer
- Poor efficacy undermines Genentech metastatic breast cancer indication for Avastin
- US Capitol Capsule: Hope not enough for Avastin in MBC; Hamburg explains withdrawal
- US FDA lawyers urge no 'do-over' for Avastin breast cancer indication
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
